AXQ Capital LP Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

AXQ Capital LP purchased a new stake in Hologic, Inc. (NASDAQ:HOLXFree Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 22,700 shares of the medical equipment provider’s stock, valued at approximately $1,575,000.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Hologic by 1.4% in the first quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock valued at $2,141,919,000 after purchasing an additional 381,608 shares during the last quarter. BlackRock Inc. grew its holdings in Hologic by 0.4% during the 2nd quarter. BlackRock Inc. now owns 23,849,548 shares of the medical equipment provider’s stock worth $1,931,098,000 after acquiring an additional 87,374 shares during the last quarter. State Street Corp increased its position in Hologic by 1.8% in the 2nd quarter. State Street Corp now owns 11,542,769 shares of the medical equipment provider’s stock valued at $934,618,000 after acquiring an additional 206,023 shares during the period. Macquarie Group Ltd. raised its stake in shares of Hologic by 227.2% during the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after acquiring an additional 4,363,687 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Hologic by 1.3% during the second quarter. Geode Capital Management LLC now owns 5,391,310 shares of the medical equipment provider’s stock worth $435,426,000 after purchasing an additional 69,276 shares during the period. 92.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Royal Bank of Canada lowered their target price on shares of Hologic from $74.00 to $72.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. Needham & Company LLC upped their price target on shares of Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 2nd. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday. Raymond James raised their price target on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Finally, UBS Group increased their target price on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Hologic has a consensus rating of “Hold” and an average price target of $86.89.

Check Out Our Latest Report on Hologic

Insider Buying and Selling at Hologic

In related news, Director Scott T. Garrett sold 10,000 shares of the stock in a transaction on Monday, December 11th. The stock was sold at an average price of $68.71, for a total value of $687,100.00. Following the transaction, the director now owns 47,039 shares of the company’s stock, valued at $3,232,049.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the transaction, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Scott T. Garrett sold 10,000 shares of the stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $68.71, for a total transaction of $687,100.00. Following the sale, the director now owns 47,039 shares of the company’s stock, valued at approximately $3,232,049.69. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

Hologic Price Performance

HOLX traded down $0.15 on Friday, reaching $73.65. 1,358,025 shares of the company’s stock were exchanged, compared to its average volume of 1,969,571. The stock has a market cap of $17.29 billion, a PE ratio of 34.91, a P/E/G ratio of 2.50 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88. The stock’s fifty day moving average price is $73.39 and its 200-day moving average price is $71.73.

Hologic (NASDAQ:HOLXGet Free Report) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same quarter in the previous year, the business earned $1.07 earnings per share. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. Sell-side analysts expect that Hologic, Inc. will post 4.02 EPS for the current year.

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Further Reading

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.